Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer

NCT00603941 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00603941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00603941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel in Subjects With Advanced Anaplastic Thyroid Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2008
Completion date
December 31, 2011
Enrollment
19 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer